Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Hangzhou Tigermed Consulting Co Ltd (Tigermed) is a clinical research organization that provides comprehensive services to the global biopharmaceutical and medical device industries. The company's activities include offering end-to-end clinical development services, from preclinical to post-marketing phases. Its services include clinical trial management, regulatory affairs, data management, and statistical analysis. Tigermed conducts research in the therapeutic areas of oncology, infections, hematology, cardiovascular, endocrinology, rheumatology, nephrology and gastroenterology. The company has operations across the Asia Pacific, Europe, North America, Latin America, and Africa. Tigermed is headquartered in Hangzhou, Zhejiang, China.
Hangzhou Tigermed Consulting Co Ltd premium industry data and analytics
Products and Services
| Services |
|---|
| Preclinical Development: |
| Medicinal Chemistry |
| Compound Screening |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In July, the company completed the acquisition of Micron,Inc. |
| 2023 | Corporate Changes/Expansions | In August, the company opened international headquarters in Hong Kong. |
| 2023 | Acquisitions/Mergers/Takeovers | In January, the company announced the acquisition of Marti Farm. |
Competitor Comparison
| Key Parameters | Hangzhou Tigermed Consulting Co Ltd | WuXi AppTec Co Ltd | Pharmaron Beijing Co Ltd | Boji Medical Technology Co Ltd |
|---|---|---|---|---|
| Headquarters | China | China | China | China |
| City | Hangzhou | Shanghai | Beijing | Guangzhou |
| State/Province | Zhejiang | Shanghai | Beijing | Guangdong |
| No. of Employees | 11,130 | 33,834 | 25,088 | 1,169 |
| Entity Type | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ye Xiaoping | Chairman | Executive Board | 2023 | 63 |
| Cao Xiaochun | President; General Manager; Director | Executive Board | 2019 | 57 |
| Wen Zengyu | Director; Deputy General Manager; Co-President | Executive Board | 2023 | 46 |
| Yang Chengcheng | Chief Financial Officer; Senior Vice President | Senior Management | 2022 | 52 |
| Yifei Peng | Executive Vice President; Chief Operating Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer